Durable clinical and radiographic responses in a series of patients with HER2+Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd)
Publication
, Conference
Alder, L; Trapani, D; Van Swearingen, A; Khasraw, M; Anders, C; Lin, N; Sammons, S
Published in: CANCER RESEARCH
2022
Duke Scholars
Published In
CANCER RESEARCH
EISSN
1538-7445
ISSN
0008-5472
Publication Date
2022
Volume
82
Issue
12
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3101 Biochemistry and cell biology
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Alder, L., Trapani, D., Van Swearingen, A., Khasraw, M., Anders, C., Lin, N., & Sammons, S. (2022). Durable clinical and radiographic responses in a series of patients with HER2+Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd). In CANCER RESEARCH (Vol. 82).
Alder, Laura, Dario Trapani, Amanda Van Swearingen, Mustafa Khasraw, Carey Anders, Nancy Lin, and Sarah Sammons. “Durable clinical and radiographic responses in a series of patients with HER2+Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd).” In CANCER RESEARCH, Vol. 82, 2022.
Alder L, Trapani D, Van Swearingen A, Khasraw M, Anders C, Lin N, et al. Durable clinical and radiographic responses in a series of patients with HER2+Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd). In: CANCER RESEARCH. 2022.
Alder, Laura, et al. “Durable clinical and radiographic responses in a series of patients with HER2+Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd).” CANCER RESEARCH, vol. 82, no. 12, 2022.
Alder L, Trapani D, Van Swearingen A, Khasraw M, Anders C, Lin N, Sammons S. Durable clinical and radiographic responses in a series of patients with HER2+Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd). CANCER RESEARCH. 2022.
Published In
CANCER RESEARCH
EISSN
1538-7445
ISSN
0008-5472
Publication Date
2022
Volume
82
Issue
12
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3101 Biochemistry and cell biology
- 1112 Oncology and Carcinogenesis